|Articles|January 6, 2022
Daily Medication Pearl: Anifrolumab-fnia (Saphnelo)
Author(s)Saro Arakelians, PharmD
Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody indicated for the treatment of moderate to severe systemic lupus erythematosus.
Advertisement
Medication Pearl of the Day: Anifrolumab-fnia (Saphnelo)
Indication: Saphnelo is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus, who are receiving standard therapy.
Insight:
- Dosing: The recommended dosage is 300 mg as an intravenous infusion over a 30-minute period every 4 weeks.
- Dosage forms: Injection 300 mg/2 mL (150 mg/mL) in a single-dose vial.
- Adverse events: Most common adverse drug reactions (incidence ≥5%) are nasopharyngitis, upper respiratory tract infections, bronchitis, infusion-related reactions, herpes zoster, and cough.
- Mechanism of action: Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs.
- Manufacturer: AstraZeneca
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
4
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
5